Aptensio XR
(methylphenidate XR)
| Full Prescribing Information | DailyMed Drug Information |
Forms/Strengths
- Capsules: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg
Dosing
- Age: ≥ 6 y/o
- Onset: ~ 60-120 min
- Duration: 8-12 hours
- Release Profile: 40% IR, 60% ER
- Considerations: Capsules may be swallowed whole or opened, and the entire contents can be sprinkled on applesauce.
- Initial Dose: 10 mg
- Titration: 10 mg weekly
- Max Dose: 60 mg/day
Quick Facts
- Blocks reuptake of dopamine and norepinephrine via DAT and NET inhibition, increasing synaptic levels primarily in prefrontal cortex for improved attention and impulse control
- Biphasic release: ~50% immediate-release beads, ~50% delayed-release beads for rapid onset and sustained effect
- Common side effects include appetite suppression, insomnia, and mild cardiovascular changes
- Black box warning: Potential for abuse, misuse, and dependence; sudden death reported in patients with structural cardiac abnormalities
- Monitor growth in children; caution in patients with tics, bipolar disorder, or psychosis
- Not for use within 14 days of MAOIs due to hypertensive crisis risk
Indications
- ADHD (ICD-10: F90.0)
Off-Label Uses
- Narcolepsy (ICD-10: G47.411): Occasionally used for daytime sleepiness
- Treatment-resistant depression (ICD-10: F32.x, F33.x): Adjunct for augmentation in select cases
How to Take
- Administration: Once daily in the morning with or without food; high-fat meals may delay Tmax and increase exposure; do not crush/chew capsules; if unable to swallow, sprinkle entire contents on ≤1 tablespoon applesauce and swallow immediately
- Missed Dose: Take next dose as scheduled; do not double dose
- Discontinuation/Tapering: May discontinue abruptly after short-term use; taper if long-term (>4 weeks) or high-dose to minimize rebound symptoms
Side Effects
- Common:
- Appetite/weight loss
- Insomnia, headache
- Abdominal pain, nausea, dry mouth
- Increased heart rate/blood pressure, anxiety/irritability
- Serious:
- Black box warning: Drug abuse/dependence; assess risk prior to use
- Cardiovascular: Sudden death/myocardial infarction in patients with cardiac disease, priapism
- Psychiatric: Psychosis, mania, aggression, suicidal ideation
- Peripheral vasculopathy (e.g., Raynaud's): Digital ulceration
- Hypersensitivity: Rash, anaphylaxis
Monitoring / Labs
- Baseline and periodic: Heart rate, blood pressure, weight/height (pediatrics)
- Psychiatric status for new/worsening symptoms
- Growth parameters every 3-6 months in children; consider drug holiday
- CBC, CMP if long-term use; signs of abuse/diversion
Education
-
When to Call the Doctor:
- Severe mood changes, aggression, or suicidal thoughts.
- Chest pain, rapid heartbeat, shortness of breath (cardiovascular concerns).
- Uncontrolled movements, tics, or worsening anxiety.
- Numbness, coldness, or color changes in fingers or toes (circulatory issues).
- Unexplained weight loss or delayed growth in pediatric patients.
-
Safety Tips:
- Monitor blood pressure and heart rate, especially in patients with cardiovascular risk.
- Use caution in patients with anxiety, bipolar disorder, or psychosis, as symptoms may worsen.
- Avoid caffeine and other stimulants, which may amplify side effects.
- Ensure adequate hydration and nutrition, as appetite suppression is common.
- Tapering may be required if discontinuing after long-term use.
-
Parent Tips for Pediatric Patients:
- Encourage a nutrient-dense diet to counteract appetite suppression.
- Administer in the morning before school for optimal effect.
- Monitor school performance and behavioral changes.
- Observe for sleep disturbances; adjust timing if necessary.
- Communicate regularly with teachers and caregivers about medication effects.
Additional Information
-
Contraindications:
- Hypersensitivity to methylphenidate
- Concurrent/use within 14 days of MAOIs
- Glaucoma, severe hypertension, symptomatic cardiac disease
- Pregnancy: Category C (older); limited human data—use if benefit outweighs risk; neonatal withdrawal possible
- Lactation: Present in breast milk; weigh risks (irritability, reduced weight gain in infant)
- Drug Interactions:
- MAOIs/serotonergics: Hypertensive crisis/serotonin syndrome
- CYP2D6 inhibitors (e.g., bupropion): Increased methylphenidate levels
- Acidifiers (e.g., vitamin C): Decreased absorption; alkalinizers (e.g., antacids): Increased absorption
- Pressors (e.g., alpha-agonists): Potentiated hypertension
- Alcohol: Accelerated release from capsules
References
- FDA. Concerta (methylphenidate HCl) Prescribing Information, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021121s042lbl.pdf
- DailyMed. Methylphenidate Hydrochloride Extended-Release Capsules, 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=example (generic XR capsules)
- UpToDate. Methylphenidate: Drug information, 2025. https://www.uptodate.com/contents/methylphenidate-drug-information
- American Academy of Pediatrics. ADHD Clinical Practice Guideline, 2021. https://publications.aap.org/pediatrics/article/148/6/e2021055352/180000/Clinical-Practice-Guideline-for-the-Diagnosis